石四藥集團(02005.HK)上半年純利升11.6%至2.76億港元 中期息5港仙
格隆匯8月27日丨石四藥集團(02005.HK)公佈截至2021年6月30日止6個月的中期業績,期內集團實現銷售收入24.43億港元,同比增長37.0%,同期毛利率60.2%,同比下降3.8個百分點;公司股權持有人應占溢利2.76億港元,同比增長11.6%;每股基本盈利0.0910港元,宣派中期股息每股0.05港元。
靜脈輸液的收益為15.27億港元,較去年同期增加29.1%。其中,非PVC軟袋及直立式軟袋輸液的收益分別為7.78億港元及2.80億港元,總額為10.58億港元,較去年同期增加36.8%,並佔靜脈輸液的收益69.3%;PP塑瓶輸液的收益為3.61億港元,較去年同期增加21.5%,並佔靜脈輸液的收益23.6%;玻璃瓶輸液的收益為1.08億港元,較去年同期減少3.2%,並佔靜脈輸液的收益7.1%。
整體毛利率由去年同期的64.0%下跌3.8個百分點至60.2%,主要由於生產成本整體呈上升趨勢,且毛利率低於成藥的原料藥於收益佔比增加所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.